trending Market Intelligence /marketintelligence/en/news-insights/trending/01Vhrr1RxJpceBZ7wFYG0A2 content esgSubNav
In This List

Cerulean's chief medical officer, chief scientific officer set for exit

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Cerulean's chief medical officer, chief scientific officer set for exit

Cerulean Pharma Inc. and Adrian Senderowicz, senior vice president and chief medical officer, agreed that Senderowicz's employment with the company will end June 15.

In addition, the company and Scott Eliasof, senior vice president and chief scientific officer, agreed that Eliasof's employment with Cerulean will end June 30.

Senderowicz and Eliasof's decisions to terminate their employment did not involve any disagreements with the company, its management or the board.